Intravesicular Onabotulinumtoxin A in Interstitial Cystitis

Status Completed

Clinical Trial Summary

The purpose of this research study is to identify the optimal usage of Onabotulinumtoxin A in interstitial cystitis. Onabotulinumtoxin A, more commonly known by the trade name Botox®, is a medication that comes from the bacteria Clostridium botulinum. It works by blocking the release of the neurotransmitter acetylcholine(a chemical messenger that carries signals between nerve cells and other cells in the body). Blocking that neurotransmitter results in decreased muscle activity.

Clinical Trial Description

The purpose of this study is to evaluate the efficacy of intravesicular Onabotulinumtoxin A injections for the treatment of interstitial cystitis (IC). Specifically, we hypothesize that trigonal Onabotulinumtoxin A injections is an effective treatment for IC and will result in more subjective and objective symptom relief than posterior wall Onabotulinumtoxin A injections. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02297100
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact
Status	Completed
Phase	Phase 4
Start date	December 2014
Completion date	January 10, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04313972` - IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone	Phase 4
Completed	`NCT03282318` - A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis	Phase 2
Completed	`NCT03463499` - The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients	N/A
Completed	`NCT02898220` - Trans-MAPP II Study of Urologic Chronic Pelvin Pain
Terminated	`NCT02591199` - Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome	Phase 2
Completed	`NCT02247557` - Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis	Phase 2
Active, not recruiting	`NCT01731470` - Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)	N/A
Completed	`NCT01197261` - OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)	Phase 2
Completed	`NCT00971568` - Urinary Biomarkers Characteristic to Interstitial Cystitis	N/A
Completed	`NCT00527917` - A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.	Phase 2
Completed	`NCT00150488` - URACYST® For the Treatment of GAG Deficient Interstitial Cystitis	N/A
Recruiting	`NCT00094874` - Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms	Phase 3
Terminated	`NCT00086684` - Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis	Phase 4
Recruiting	`NCT04845217` - Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome	Phase 1/Phase 2
Completed	`NCT04401176` - Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome	Phase 2
Recruiting	`NCT05147779` - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis	Phase 1
Suspended	`NCT04450316` - Low-dose Naltrexone for Bladder Pain Syndrome	Phase 2
Completed	`NCT04010513` - Hypnosis for Bladder Pain Syndrome	N/A
Completed	`NCT05179460` - A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
Completed	`NCT02232282` - Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial	N/A